Tan, M YSyngelaki, APoon, L CRolnik, D LO'Gorman, NDelgado, J LAkolekar, RKonstantinidou, LTsavdaridou, MGaleva, SAjdacka, UMolina, F SPersico, NJani, J CPlasencia, WGreco, EPapaioannou, GWright, AWright, DNicolaides, K H2023-01-252023-01-252018-07-11http://hdl.handle.net/10668/12584To examine the performance of screening for early, preterm and term pre-eclampsia (PE) at 11-13 weeks' gestation by maternal factors and combinations of mean arterial pressure (MAP), uterine artery (UtA) pulsatility index (PI), serum placental growth factor (PlGF) and serum pregnancy-associated plasma protein-A (PAPP-A). The data for this study were derived from three previously reported prospective non-intervention screening studies at 11 + 0 to 13 + 6 weeks' gestation in a combined total of 61 174 singleton pregnancies, including 1770 (2.9%) that developed PE. Bayes' theorem was used to combine the prior distribution of gestational age at delivery with PE, obtained from maternal characteristics, with various combinations of biomarker multiples of the median (MoM) values to derive patient-specific risks of delivery with PE at In pregnancies that developed PE, compared to those without PE, the MoM values of UtA-PI and MAP were increased and those of PAPP-A and PlGF were decreased, and the deviation from normal was greater for early than late PE for all four biomarkers. Combined screening by maternal factors, UtA-PI, MAP and PlGF predicted 90% of early PE, 75% of preterm PE and 41% of term PE, at a screen-positive rate of 10%; inclusion of PAPP-A did not improve the performance of screening. The performance of screening depended on the racial origin of the women; on screening by a combination of maternal factors, MAP, UtA-PI and PlGF and using a risk cut-off of 1 in 100 for PE at Screening by maternal factors and biomarkers at 11-13 weeks' gestation can identify a high proportion of pregnancies that develop early and preterm PE. © 2018 Crown copyright. Ultrasound in Obstetrics & Gynecology © 2018 ISUOG.enASPREBayes' theoremSPREEaspirinfirst-trimester screeningmean arterial pressureplacental growth factorpregnancy-associated plasma protein-Apyramid of pregnancy caresurvival modeluterine artery DopplerAdultArterial PressureBayes TheoremBiomarkersFemaleGestational AgeHumansPlacenta Growth FactorPre-EclampsiaPregnancyPregnancy Trimester, FirstPregnancy-Associated Plasma Protein-AProspective StudiesPulsatile FlowRisk AssessmentUterine ArteryVascular Endothelial Growth Factor Receptor-1Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation.research article29896812open access10.1002/uog.191121469-0705https://obgyn.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/uog.19112